An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough

Rayid Abdulqawi, Imran Satia, Kimberley J. Holt, Rachel Dockry, Shilpi Sen, Jaclyn A. Smith

Source: ERJ Open Res, 7 (3) 00447-2021; 10.1183/23120541.00447-2021
Journal Issue: July

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Rayid Abdulqawi, Imran Satia, Kimberley J. Holt, Rachel Dockry, Shilpi Sen, Jaclyn A. Smith. An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. ERJ Open Res, 7 (3) 00447-2021; 10.1183/23120541.00447-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 674s
Year: 2007

Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Comparitive study for evaluation of efficacy and safety of doxofylline and theophylline in chronic persistent asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009


Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study
Source: Eur Respir J 2005; 26: Suppl. 49, 253s
Year: 2005

Efficacy of azithromycin in severe asthma from the AMAZES randomised trial
Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Year: 2019



Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Year: 2019




Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection
Source: Virtual Congress 2020 – Chinese programme 2020: Part I
Year: 2020


Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

A randomized, double-blind, placebo-controlled trial on the effect of intranasal corticosteroid as a treatment for moderate to severe obstructive sleep apnea with coexisting chronic rhinitis
Source: International Congress 2019 – Current perspectives in sleep-disordered breathing
Year: 2019


Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006